Relmada Therapeutics (RLMD) Short-Term Debt issuances (2019 - 2020)
Relmada Therapeutics' (RLMD) quarterly Short-Term Debt issuances came in at -$110247.0 in Q1 2020, down 28.24% year-on-year from -$153633.8 in Q2 2019, and up 50.57% on a QoQ basis from -$223017.0 in Q3 2019.
Relmada Therapeutics (RLMD) Short-Term Debt issuances (2019 - 2020) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Short-Term Debt issuances data on file, last reported at -$110247.0 in Q1 2020.
- On a quarterly basis, Short-Term Debt issuances fell 28.24% year-over-year to -$110247.0 in Q1 2020; TTM through Sep 2020 was -$333264.0, a N/A change from a year earlier, with the FY2019 full-year figure at -$285170.0, down 3454.94% from the prior year.
- Short-Term Debt issuances for Q1 2020 stood at -$110247.0, up from -$223017.0 in the prior quarter.
- Over the last five years, Short-Term Debt issuances for RLMD reached as high as -$85969.0 in Q1 2019 and fell as low as -$223017.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 58.20 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -110,247.00 |
| Mar 31, 2020 | -110,247.00 |
| Sep 30, 2019 | -223,017.00 |
| Sep 30, 2019 | -223,017.00 |
| Jun 30, 2019 | -114,738.00 |
| Jun 30, 2019 | -114,738.00 |
| Mar 31, 2019 | -85,969.00 |
| Mar 31, 2019 | -85,969.00 |